156 related articles for article (PubMed ID: 30688024)
1. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile.
Parodi S; Pistorio A; Erminio G; Ognibene M; Morini M; Garaventa A; Gigliotti AR; Haupt R; Frassoni F; Pezzolo A
Pediatr Blood Cancer; 2019 May; 66(5):e27635. PubMed ID: 30688024
[TBL] [Abstract][Full Text] [Related]
2. Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.
Brisse HJ; Blanc T; Schleiermacher G; Mosseri V; Philippe-Chomette P; Janoueix-Lerosey I; Pierron G; Lapouble E; Peuchmaur M; Fréneaux P; Galmiche L; Algret N; Peycelon M; Michon J; Delattre O; Sarnacki S
PLoS One; 2017; 12(9):e0185190. PubMed ID: 28945781
[TBL] [Abstract][Full Text] [Related]
3. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
Pinto N; Mayfield JR; Raca G; Applebaum MA; Chlenski A; Sukhanova M; Bagatell R; Irwin MS; Little A; Rawwas J; Gosiengfiao Y; Delattre O; Janoueix-Lerosey I; Lapouble E; Schleiermacher G; Cohn SL
Pediatr Blood Cancer; 2016 Jun; 63(6):1019-23. PubMed ID: 26864375
[TBL] [Abstract][Full Text] [Related]
4. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
5. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of segmental alterations determines progression in neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Ribeiro A; Klijanienko J; Couturier J; Pierron G; Mosseri V; Valent A; Auger N; Plantaz D; Rubie H; Valteau-Couanet D; Bourdeaut F; Combaret V; Bergeron C; Michon J; Delattre O
J Clin Oncol; 2010 Jul; 28(19):3122-30. PubMed ID: 20516441
[TBL] [Abstract][Full Text] [Related]
7. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
8. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
9. Distribution of segmental chromosomal alterations in neuroblastoma.
Juan Ribelles A; Gargallo P; Ferriol C; Segura V; Yáñez Y; Juan B; Cañada AJ; Font de Mora J; Cañete A; Castel V
Clin Transl Oncol; 2021 Jun; 23(6):1096-1104. PubMed ID: 32948984
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
11. Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
[TBL] [Abstract][Full Text] [Related]
12. Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.
Pezzolo A; Rossi E; Gimelli S; Parodi F; Negri F; Conte M; Pistorio A; Sementa A; Pistoia V; Zuffardi O; Gambini C
Neuro Oncol; 2009 Apr; 11(2):192-200. PubMed ID: 18923191
[TBL] [Abstract][Full Text] [Related]
13. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
14. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
15. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
[TBL] [Abstract][Full Text] [Related]
16. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
17. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
[TBL] [Abstract][Full Text] [Related]
18. Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without
Wieczorek A; Szewczyk K; Klekawka T; Stefanowicz J; Ussowicz M; Drabik G; Pawinska-Wasikowska K; Balwierz W
Front Oncol; 2023; 13():1134772. PubMed ID: 36865795
[TBL] [Abstract][Full Text] [Related]
19. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
20. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
